Recent Press Releases

Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

- Company to host conference call tomorrow, September 18, 2014 at 9:00 a.m. ET to discuss the clinical hold BURLINGTON, Mass., Sept. 17, 2014 -- Flexion Therapeutics, Inc. today announced that the...

Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab

WHITEHOUSE STATION, N.J., and MUMBAI, India, Sep 17, 2014 (BUSINESS WIRE) -- Merck & Co., Inc., MRK, -0.40% known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries...

Tokai Pharmaceuticals Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--Sep. 17, 2014-- Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven...

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA,...

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

-- Data to be Presented at European Society for Medical Oncology Congress in Madrid -- FOSTER CITY, Calif.--Sep. 17, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2...

Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock

Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock - Endo's Proposal Provides Auxilium Shareholders with Substantial Premium, Immediate Cash...

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease Tuesday, 16 September 2014 AstraZeneca and Eli Lilly and Company (Lilly) today...

Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target

Five Prime Therapeutics, Inc. FPRX, +1.82% (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases,...

FDA approves Movantik for opioid-induced constipation

The U.S. Food and Drug Administration today approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. Opioids are a class of drugs that...

University of California proposes creation of new venture fund to invest in UC innovation

The University of California today (Sept. 15) announced the creation of UC Ventures, an independent fund to pursue investments in UC research-fueled enterprises, subject to the approval of the UC...

SIGA Technologies, Inc. Files for Chapter 11 Reorganization

NEW YORK-- SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it...

NW Bio's Cancer Vaccine Is The First Drug To Be Designated By UK Authorities As A "Promising Innovative Medicine" (PIM)

"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, MD, September 16, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology...

New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes

Vienna, Austria, 16 September - Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The...

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016

THOUSAND OAKS, Calif. and

Akashi Therapeutics Acquires Global Rights to Novel DMD Treatment from Tonus Therapeutics

Akashi Therapeutics Acquires Global Rights to Novel DMD Treatment from Tonus Therapeutics GsMTx-4 Addresses Calcium Level Imbalance - a Critical Area of Need in DMD Cambridge, Mass.—September...

FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism

BEDMINSTER, N.J.--NPS Pharmaceuticals, Inc. (NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced...

FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency

DEERFIELD, Ill. & SAN DIEGO, Sep 12, 2014 -- Baxter International Inc. and Halozyme Therapeutics, Inc., today announced that the United States Food and Drug Administration (FDA) approved...